<DOC>
	<DOCNO>NCT01408082</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy safety ISV-502 compare AzaSiteÂ® alone , Dexamethasone alone , vehicle treatment subject Non-bacterial Blepharitis .</brief_summary>
	<brief_title>Efficacy Safety Study Steroid/Antibiotic Combination Eyedrop Treat Non-Bacterial Blepharitis</brief_title>
	<detailed_description />
	<mesh_term>Blepharitis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Are least 18 year age Visit 1 ( Day 1 , Baseline ) either sex race . Signature subject legally authorize representative Informed Consent Form . Are willing able follow instruction attend study visit . Are willing avoid disallow medication duration study . If female childbearing potential , agree submit urine sample pregnancy test . Post menopausal define menses least 12 consecutive month . Additional inclusion criterion also apply . Have know sensitivity poor tolerance component Investigational Drug . Have acute ocular infection ( bacterial , viral fungal ) active ocular inflammation Blepharitis study eye . Have use topical corticosteroid medication topical ophthalmic solution investigator feel may interfere study parameter . Have use nondiagnostic topical ophthalmic solution study eye . Be currently pregnant , nursing , plan pregnancy ; woman positive urine pregnancy test . Currently suffer alcohol and/or drug abuse . Have prior ( within 30 day begin dose ) anticipate concurrent use investigational drug device . Have condition situation , Investigator 's opinion , may put subject increase risk , confound study data , interfere significantly subject 's study participation . Additional exclusion criterion also apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>